Comments
Shares of Biocon hit a record high as the EU regulator has okayed the company's marketing applications for generic cancer drugs.
Biocon Ltd jumped as much as 3.6 per cent to touch a record high of Rs 447.60.
The company's partner Mylan N.V. had said on Thursday that the European Medicines Agency (EMA) had accepted the marketing authorisation applications for the proposed generic drugs trastuzumab, pegfilgrastim.
Trastuzumab is used as a treatment for breast and gastric cancers, while pegfilgrastim is used to bolster neutrophils, a kind of white blood cell, in cancer patients treated with chemotherapy.
Up to Thursday's close, the stock had risen 36.49 per cent this year.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.